Skip to content

Transcutaneous Auricular Vagal Nerve Stimulation for Functional Dyspepsia With Sleep Disturbances: a Randomized Controlled Trial

Transcutaneous Auricular Vagal Nerve Stimulation for Functional Dyspepsia With Sleep Disturbances: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05827575
Enrollment
60
Registered
2023-04-25
Start date
2022-03-30
Completion date
2023-06-30
Last updated
2023-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia, Sleep Disturbances

Keywords

Transcutaneous Auricular Vagal Nerve Stimulation, Functional Dyspepsia, Sleep Disturbances

Brief summary

Functional dyspepsia(FD) is most common in functional gastrointestinal disorders whose rick factors include sleep disturbances. The medication treatment for functional dyspepsia with sleep disturbances has disadvantages such as addiction and withdrawal symptoms. Transcutaneous auricular vagal nerve stimulation(taVNS) is a new therapeutic method to improve dyspepsia and sleep. Study on taSNS for FD with sleep disturbances has not yet been explored.

Detailed description

Functional dyspepsia (FD) is most common in functional gastrointestinal disorders whose risk factors include sleep disturbances. The medication treatment for FD with sleep disturbances has disadvantages such as addiction and withdrawal symptoms. Transcutaneous auricular vagal nerve stimulation (taVNS) is a new therapeutic method to improve dyspepsia and sleep. The study on taVNS for FD with sleep disturbances has not yet been explored.60 participants who have FD and sleep disturbances are recruited from the department of the Second Affiliated Hospital of Xi'an Jiaotong University. Inclusion criteria follows: meeting the ROME IV diagnostic criteria of FD; Pittsburgh Sleep Quality Index(PSQI)\>7; aged 18-65 years old; not taking related drugs in past one month; from March 2022 to June 2023; sign informed consent. All patients were randomly divided into 2 groups and respectively treated with taVNS and sham-taVNS for four weeks. PSQI, Nepean dyspepsia index (NDI), electrogastrogram (ECG), nutrient drinking satiety test, Hamilton Anxiety and Depression Scale, heart rate variability (HRV) and serum melatonin (MLT) were recorded at baseline and after 4-week treatment. The effect and mechanism of taVNS for FD with sleep disturbances were investigated by comparing the indexes before and after treatment of taVNS and sham-taVNS groups. The study was proved by the medical ethics committee of the Second Affiliated Hospital of Xi'an Jiaotong University.

Interventions

stimulation on both ear within different area for 4 weeks;parameter:2s on,3s off,0.5ms,25hz

Sponsors

Second Affiliated Hospital of Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of Functional bloating/distension with Rome IV; 2. Pittsburgh Sleep Quality Index(PSQI)\>7; 3. Aged 18-65 years old;

Exclusion criteria

1. Have taken drugs that may affect gastrointestinal motility and sleep in the past two week; 2. The history of gastrointestinal surgery; 3. With severe heart, liver and kidney diseases; 5.Pregnant and breastfeeding women; 6.Skin allergies.

Design outcomes

Primary

MeasureTime frameDescription
Dyspepsia scoreafter 4 weeks taVNS treatmentNepean Dyspepsia Index:the symptom severity score and life quality score
Sleep scoreafter 4 weeks taVNS treatmentPittsburgh Sleep Quality Index
Hamilton Anxiety and Depression Scale scoreafter 4 weeks taVNS treatmentScore of Hamilton Anxiety and Depression Scale
Gastric slow waves in electrogastrographafter 4 weeks taVNS treatmentThe percentage of the normal gastric slow waves in fasting, fed states and the post-preprandial EGG power ratio
The threshold volume(TV)and maximal volume(MV)after 4 weeks taVNS treatmentNutrient drinking satiety test: drink \[100 g milk powder, 50 g chocolate powder (Cola Coa, Idilia Foods), and 1,120 mL water (0.6 Cal/mL, fat:19%, protein: 18%, carbohydrate: 63%)\] at a speed of 60mL/min until reaching the threshold volume(TV)and maximal volume(MV).
Heart rate variability(HRV)after 4 weeks taVNS treatmentAssessment of autonomic function with heart rate variability
Serum melatonin (MLT) levelafter 4 weeks taVNS treatmenttest the level of serum melatonin

Countries

China

Contacts

Primary ContactFei Dai
daifei68@hotmail.com13772151298
Backup ContactJingyao Li
893139621@qq.com18392702742

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026